Abstract:Objective To evaluate the efficacy and safety of two dose levels of gliclazide MR (30 mg/d and 60 mg/d) in the treatment of Chinese patients with newly diagnosed type 2 diabetes mellitus (T2DM),and its effects on insulin resistance and β-cell function.Methods A total of 120 subjects with newly diagnosed T2DM were randomized to receive 30 mg/d (Group 30 mg)or 60 mg/d (Group 60 mg) of gliclazide MR in the proportion of 1 to 1 according to random number table for 16 weeks.Glycated hemoglobin A1c (HbA1c)was measured as major efficacy index,and secondary indices such as fasting plasma glucose (FPG),two-hour postprandial plasma glucose (2 h PG),7-point glucose profile,area under curve of insulin (AUC1NS),insulin sensitivity index (SEN)and the indices of the β-cell secretory function [including early insulin secretion index (ΔI30/ΔG30),basic insulin secretion index (HOMA-β)and modified β-cell function (MBCI)].Safety was assessed by adverse events (AEs),and so on.The difference of the measurement data was compared with the t test.The Wilcoxon test was used to assess the statistical difference among the groups.Results At 16 weeks,the change from baseline in HbA 1 c was-1.2％± 1.1％ in the Group 30 mg and-2.2％± 1.4％ in the Group 60 mg,intergroup comparison with baseline HbA1c as a covariate showed that the descent range in the Group 60 mg was more significant (F=4.2,P=0.04).There was no intergroup difference in the change from baseline of FPG,2 hPG and 7-point glucose profile.Also,no intergroup difference was noted in the change from baseline of AUCINS and ΔI30/ΔG30.After treatment,the index of HOMA-β had a significant increasing amplitude in the Group 60 mg compared to that in the Group 30 mg (t=1951.0,P=0.04).The incidence of hypoglycemia related to study drug was 10.5％ (6/57)in the Group 30 mg and 16.1％(9/56)in the Group 60 mg.To the end of follow-up,no significant difference in the body mass index was found between the two groups[(24.8±2.6)kg/m2 in Group 30 mg and(24.2±2.5)kg/m2 in Group 60 mg,t=1.09,P＞0.05].Conclusion The dose regimen of gliclazide MR 60 mg/d is superior to 30 mg/d in the improvement of HbA1c and β-cell function for Chinese patients with newly diagnosed T2DM ;however,dosage of 60 mg/d increases the incidence of slight hypoglycemia events.Thus,for patients with newly diagnosed T2DM,selection of initial therapy dose should be patient-tailored,based on clinical features of β cell function and hypoglycemia risks.

Clinical Study of Controlled-Release formula of Glipizide in the Treatment of Coronary Artery Disease Complicated with Type 2 Diabetes Mellitus

Efficacy and Safety in Type 2 Diabetes Treated by Controlled-release-gliclazide in Comparison with Gliclazide

Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: analysis of results from the CONSENT trial.

Lipid Profiling Reveals Different Therapeutic Effects of Metformin and Glipizide in Patients with Type 2 Diabetes and Coronary Artery Disease

A Double-Blind Randomized Multiple Center Clinical Trial on Observing the Effect of Fixed-Dose Glipizide/metformin on Type 2 Diabetes

Comparison of Controlled-Release Formulation of Glipizide and Immediate-Release Glipizide in Clinical Efficacy and Safety

Efficacy and safety of rosiglitazone hydrochloride in the treatment of patients with type 2 diabetes mellitus

Clinical Effects of Gliclazide Sustained-Release Tablets on Type 2 Diabetes Mellitus

Comparison of Efficacy and Quality of Life in Type 2 Diabetics Treated with Controlled-Release-gliclazide and Ordinary Gliclazide Tablets

Efficacy and Safety Between Two Dosages of Gliclazide Modified Release Tablets (30 Mg and 60 Mg Once Daily) in the Treatment of Patients with Newly Diagnosed Type 2 Diabetes

A Multicenter Clinic Study of Slow-Release-gliclazide in Type 2 Diabetes Mellitus

The glycemic control in Chinese type 2 diabetic out-patients receiving oral antidiabetic agents and the efficacy and safety of optimized modified-release gliclazide treatment

Clinical efficacy of glimepiride combined with pioglitazone on glycemic control in type 2 diabetes patients

PP93 Efficacy of Pharmacological Treatments for Type 2 Diabetes in China

The Efficacy and Safety of Glimepiride in Treatment of Type 2 Diabetes

Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs.

Multi-center,randomized,double-masked,double-mimic Active-Controlled Clinical Trial of Glipizide/metformin Hydrochloride Tablets for Patients with Type 2 Diabetes

Comparative Efficacy and Safety of Glucose-Lowering Drugs as Monotherapy for Type 2 Diabetes: A Systematic Review and Indirect Treatment Comparison

Effects and patient compliance of sustained-release versus immediate-release glipizides in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

The efficacy and safety of 30 mg slow-released-gliclazide in type 2 diabetes mellitus]

Comparision of glimepiride and glibenclamide on cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus